MFG
ALNY icon

Merit Financial Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Merit Financial Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$988K Buy
3,281
+378
+13% +$114K 0.01% 1081
2026
Q1 		$960K Sell
2,903
-1,608
-36% -$547K 0.01% 998
2025
Q4 		$1.79M Buy
4,511
+279
+7% +$123K 0.01% 690
2025
Q3 		$1.93M Buy
4,232
+2,342
+124% +$954K 0.02% 587
2025
Q2 		$616K Sell
1,890
-3,424
-64% -$947K 0.01% 1004
2025
Q1 		$1.43M Buy
5,314
+2,819
+113% +$724K 0.02% 522
2024
Q4 		$587K Buy
+2,495
New +$656K 0.01% 667
2024
Q3 		– Sell
-928
Closed -$226K – 834
2024
Q2 		$226K Buy
+928
New +$147K 0.01% 828

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Merit Financial Group's ALNY Position: Q2 2026 in Review

Merit Financial Group increased its Alnylam Pharmaceuticals (ALNY) stake by 13% in Q2 2026, buying an estimated $114K and bringing the position to 3,281 shares worth $988K. The position accounts for 0.01% of the portfolio, ranked #1081.

Merit Financial Group first reported a position in ALNY in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.93M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Merit Financial Group held 3,281 shares of Alnylam Pharmaceuticals worth $988K as of Q2 2026.
  • Merit Financial Group bought 378 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $114K.
  • Alnylam Pharmaceuticals made up 0.01% of Merit Financial Group's portfolio in Q2 2026, its #1081 holding.
  • Merit Financial Group first reported a position in Alnylam Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • Merit Financial Group's Alnylam Pharmaceuticals position peaked at $1.93M in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.